A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet) Versus Diclofenac in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)

This study has been terminated.
(Due to difficult enrollment, and investigator agreed to terminate this study.)
Sponsor:
Information provided by:
Johnson & Johnson Taiwan Ltd
ClinicalTrials.gov Identifier:
NCT00766402
First received: October 3, 2008
Last updated: April 26, 2010
Last verified: April 2010
  Purpose

The purpose of the study is to investigate the clinical benefit of Tramadol/Acetaminophen (Ultracet) vs. NSAID (Diclofenac 50 mg) in the treatment of pain in patients with ankylosing spondylitis receiving stable treatment of disease modifying anti-rheumatic drugs (DMARDs).


Condition Intervention Phase
Ankylosing Spondylitis
Pain
Drug: Tramadol /acetaminophen
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study to Evaluate the Clinical Benefits of Tramadol/Acetaminophen (Ultracet) Versus Diclofenac in the Treatment of Pain in Patients With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)

Resource links provided by NLM:


Further study details as provided by Johnson & Johnson Taiwan Ltd:

Primary Outcome Measures:
  • Compare the effectiveness of Ultracet and Diclofenac based on the mean change of VAS pain score at baseline, week 2, 4, and 8

Secondary Outcome Measures:
  • Compare the Bath AS Functional Index (BASFI) and Bath AS Disease Activity Index (BASDAI) and its independent components. Evaluate the quality of life by SF-36 and its components and Safety endpoint(s) at baseline, week 2, 4, and 8.

Enrollment: 4
Study Start Date: September 2008
Study Completion Date: February 2009
Detailed Description:

This study is a single center, open labeled, randomized, parallel group trial to compare the effectiveness (pain relief) and safety of tramadol 37.5 mg and acetaminophen 325 mg (Ultracet) with Diclofenac in patients with ankylosing spondylitis receiving stable treatment of disease modifying anti-rheumatic drugs (DMARDs). Patients who meet the entry criteria will be randomized to one of the two treatment groups (Ultracet and Diclofenac). One group will treated with Tramadol 37.5 mg/Acetaminophen 325 mg combination tablet and another group will treated with Diclofenac 50 mg tablet. Patients randomized into this study will be instructed to take the one tablet Ultracet or Diclofenac 50 mg by mouth twice a day for 8 weeks. Evaluations will be performed as outlined: at screening, at baseline, and at weeks 2, 4, and 8. Non-steroidal anti-inflammatory drugs (NSAID) therapy with drugs such as indomethacin or more recently COX-2 inhibitors, are used to control the inflammation and pain in patients with ankylosing spondylitis. However, long-term usage of NSAIDs, including COX-2 inhibitors, are known to have gastrointestinal and possible cardiovascular toxic effects, which could restrict their use. Tramadol is a centrally acting analgesic compound. Acetaminophen is another centrally acting analgesic. The primary endpoint is to compare the mean change from baseline in VAS pain score between the two treatment groups (Ultracet vs Diclofenac). Other endpoints include (1) to compare the Bath AS Functional Index (BASFI) and its independent components, (2) to compare the Bath AS Disease Activity Index (BASDAI) and its independent components, and (3) to evaluate the quality of life by SF-36 and its components. The safety of Ultracet and Diclofenac in this patient population by analyzing safety data in terms of adverse events and laboratory values. Experimental Group will treated with Ultracet (Tramadol 37.5 mg/Acetaminophen 325 mg combination tablet). Control Group will treated with Diclofenac 50 mg tablet. Patients randomized into this study will be instructed to take the one tablet Ultracet or Diclofenac 50 mg twice a day for 8 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis
  • Low-back pain of at least 3 months duration improved by exercise and not relieved by rest
  • Limitation of lumbar spine in sagittal and frontal planes
  • Chest expansion decreased relative to normal values for age and sex
  • Bilateral sacroiliitis, grade 2-4 or Unilateral sacroiliitis, grade 3-4 (Stoke)
  • Patients are suffering from pain, with VAS pain score >=40 mm
  • Patients Between 18 and 70 years of age
  • Patients are receiving disease modifying anti-rheumatic drugs (DMARDs), which have reached to the stable dosage within 4 weeks prior to the randomization visit
  • Serum creatinine <=1.2 mg/dl
  • Aspartate aminotransferase (AST [SGOT]) and alanine aminotransferase (ALT [SGPT]) <= 3 times the laboratory's upper limit of normal
  • ESR (Erythrocyte Sedimentation Rate) <= 28mm/hour and CRP (C- Reactive Protein) <=0.8mg/L
  • Willingness and capability to give written informed consent, written consent for data protection, willingness to participate, and to comply with the study.

Exclusion Criteria:

  • Had an inadequate response to Tramadol HCl therapy, or have discontinued Tramadol HCl therapy due to adverse events
  • Have taken Tramadol HCl within 4 weeks prior to the entry of the study
  • Have taken other medications for pain relief within 4 weeks prior to the entry of the study, except rescue medications
  • Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease (e.g. heart failure class III/IV NYHA, cardiac infarct within last 6 month), nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders
  • Patients with a history of a severe psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study
  • Other major medical situations not suitable for the study judged by investigator's evaluation
  • Women with pregnancy or breast-feeding
  • Hepatitis B or C.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00766402

Sponsors and Collaborators
Johnson & Johnson Taiwan Ltd
Investigators
Study Director: Johnson & Johnson Taiwan, Ltd. Clinical Trial Johnson & Johnson Taiwan Ltd
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00766402     History of Changes
Other Study ID Numbers: CR015322
Study First Received: October 3, 2008
Last Updated: April 26, 2010
Health Authority: Taiwan: Department of Health

Keywords provided by Johnson & Johnson Taiwan Ltd:
Ankylosing spondylitis
Pain
Ultracet
tramadol/acetaminophen

Additional relevant MeSH terms:
Spondylitis
Spondylitis, Ankylosing
Bone Diseases, Infectious
Infection
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases
Spondylarthropathies
Spondylarthritis
Ankylosis
Joint Diseases
Arthritis
Acetaminophen
Diclofenac
Tramadol
Antirheumatic Agents
Antipyretics
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses
Anti-Inflammatory Agents, Non-Steroidal
Anti-Inflammatory Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 14, 2014